Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) has announced financial results for the fourth quarter and full year of 2012. Key results include: For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales growth driven by strong performance across the portfolio. Adjusted EPS grew 22 percent to $6.51 due to 15 percent adjusted operating income growth and lower shares outstanding;
Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
- Details
- Category: Novartis
Novartis' Group net sales reached USD 14.8 billion (0%, +2% cc) in the fourth quarter. Currency had a negative impact of 2 percentage points. Portfolio rejuvenation continued to drive overall growth for the Group, as recently launched products grew 17% over the previous-year quarter to USD 4.3 billion. These products, which include Lucentis, Gilenya, Afinitor and Tasigna, contributed 29% of Group net sales, up from 25% in the year-ago period, and more than offset the impact of generic competition in the quarter of USD 0.6 billion.
Takeda establishes new trading company and reinforces business structure in China
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda") today announced the launch of a new trading company in China, Takeda (China) International Trading Co., Ltd. ("TCIT"), which will strengthen its business structure in China, and is an important step in the local integration of Nycomed following Takeda's acquisition of Nycomed completed in September 2011.
Novartis makes progress in the fight to eliminate leprosy worldwide
- Details
- Category: Novartis
Novartis celebrates the one-year anniversary of an unprecedented, coordinated effort to eliminate or control 10 neglected tropical diseases (NTDs) by 2020. The commitment was captured in the landmark London Declaration on NTDs in which Novartis and a group of partners, including the World Health Organization (WHO), government officials from the United States, United Kingdom and United Arab Emirates governments, the World Bank and non-governmental organizations, and 13 other pharmaceutical companies pledged new and extended commitments to fight NTDs.
FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib* has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for afatinib* is currently under review for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation as detected by an FDA-approved test.
Sanofi updates its Research & Development pipeline
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) has provided an update on its Research & Development (R&D) pipeline with Dr. Elias Zerhouni, President, Global Research and Development, presenting at the JP Morgan Healthcare Conference in San Francisco, California.
Phase III data show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
- Details
- Category: Novartis
Data published in The Lancet showed that patients on Afinitor® (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression[1].
More Pharma News ...
- Bayer receives approval for new long-term contraceptive Skyla™ in the U.S.
- Abbott initiates clinical trial of Absorb TM in the United States
- Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
- Abbott completes separation of research-based pharmaceuticals business
- FDA approves ELIQUIS® (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease
- GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique